In the past period, due to the rapid development of next-generation sequencing technology,
accumulating evidence has clarified the complex role of the human microbiota in the …

Cancer remains a leading cause of death worldwide, placing a significant burden on
healthcare systems as well as the global economy. Rare cancers comprise a group of about …

PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Abstract Introduction In the phase 3 CheckMate 9LA study, nivolumab plus ipilimumab with
chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report …

Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment
of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279)
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Monotherapies with antibodies approved for severe asthma treatment were reported to be
safe, with side effects close to placebo1. The other 10 patients received one biologic for …

Importance Patients with mesothelioma often have next-generation sequencing (NGS) of
their tumor performed; tumor-only NGS may incidentally identify germline pathogenic or …

Purpose: We report the results of a phase II, randomized, window-of-opportunity trial of
neoadjuvant durvalumab versus durvalumab plus tremelimumab followed by surgery in …